Protocol Ledger

NCT04724369 · Phase III · COMPLETED

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Interventional Phase III clinical trial protocol NCT04724369 sponsored by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-18 Enrollment: 43 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04724369
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)43 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04724369
Protocol FieldVerified Registry Value
NCT IdentifierNCT04724369
Consolidated Lead SponsorInnervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment43 participants (ACTUAL)
Registered Start Date2021-11-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI